A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Latest Information Update: 17 Oct 2025
At a glance
- Drugs Cetuximab (Primary) ; FT 836 (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Fate Therapeutics
Most Recent Events
- 17 Oct 2025 New trial record